Login / Signup

Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.

George DranitsarisLesley G ShaneJean-Philippe GalanaudGunar StemerPhilippe DebourdeauSeth Woodruff
Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2017)
Secondary prophylaxis with dalteparin is a cost-effective alternative to VKA for the prevention of recurrent VTE in patients with cancer.
Keyphrases
  • venous thromboembolism
  • direct oral anticoagulants
  • case report
  • atrial fibrillation